Actavis opens €8m manufacturing facility expansion

Published: 14-Jan-2011
Finance Pharmaceutical

Doubles production capacity at Hafnarfjordur, Iceland site

Icelandic generics manufacturer Actavis Group has formally opened a new €8m expansion to its pharmaceutical manufacturing site in Hafnarfjordur. Powered solely by geothermal energy, giving it a zero carbon footprint for tablet manufacturing and packaging, the site uses no fossil fuels. The facility is fully accredited to supply the EU market.

The president of Iceland, Olafur Ragnar Grimsson, and members of parliament, attended the opening ceremony.

Claudio Albrecht, chief executive of Actavis, said: ‘This latest investment increases the production capacity in Iceland by 50%, giving us a significantly increased launch capability for the EU market. This is our principal development and launch site for Europe. We're proud to be able create jobs in Iceland by expanding this site.’

The production capacity of the Hafnarfjordur site is about 1.5 billion tablets, around 96% of which are exported to the European markets.

Actavis operates 14 manufacturing sites in 12 countries and employs around 10,000 people. Total production capacity is the equivalent of about 24bn tablets.

  • Companies:
  • Actavis
See more

You may also like

Regulatory

Pharma companies fined £45m for 'pay-for-delay'

Read more
GSK’s conduct, in making payments to induce companies to delay their efforts to enter the UK paroxetine market infringed the competition law prohibition on abuse of a dominant position

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Lonza aims to tackle bias concerns during blinded clinical trials Lonza has introduced an over-encapsulation product aimed at tackling concerns around bias during blinded clinical trials
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

Pharma companies fined £45m for 'pay-for-delay'

GSK’s conduct, in making payments to induce companies to delay their efforts to enter the UK paroxetine market infringed the competition law prohibition on abuse of a dominant position
Finance

Amneal to purchase generics business of Actavis Australia

Financial terms are not disclosed by the companies
Regulatory

Actavis gets go-ahead from European Commission to purchase Allergan

Deal will create one of the top 10 global pharmaceutical companies by sales revenue
Finance

Actavis plans to change name to Allergan after acquisition closes

Will retain Actavis name for certain geographic regions and product portfolios
Research & Development

Actavis to divest Pharmatech to TPG

TPG to focus on growth and development of innovative products
Regulatory

Nearly 90,000 Gabapentin capsules are recalled by Aurobindo Pharma and Actavis

The capsules were manufactured at two plants in India
Finance

Actavis to buy Auden Mckenzie for £306m

A move that will make Actavis the leading supplier of generics in the UK
Subscribe now